<?xml version="1.0" encoding="UTF-8"?>
<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 22, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01534533</url>
  </required_header>
  <id_info>
    <org_study_id>NNSFC-30972472</org_study_id>
    <secondary_id>XLin</secondary_id>
    <nct_id>NCT01534533</nct_id>
  </id_info>
  <brief_title>Effects of Lutein Supplementation on Subclinical Atherosclerosis</brief_title>
  <official_title>The Effects of Lutein Supplementation on Subclinical Atherosclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to investigate the possible positive effects of lutein and lycopene
      supplementation on early atherosclerosis in Beijing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atherosclerosis is the primary cause of cardiovascular and cerebrovascular diseases, both of
      which are the top two causes of death in industrialized countries including China. Lutein was
      found to be protective against atherosclerosis in some case control studies. However, the
      intervention on atherosclerosis have not been reported. In the present study, 192 subjects
      were randomly assigned to four groups treated with different amounts of lutein. The
      investigators observe the changes of serum lutein concentration by hyper-pressure liquid
      chromatography (HPLC), and compare the differences of common carotid IMT and arterial
      stiffness by carotid ultrasonography before and after the intervention. Serum biochemistry
      indexes including cholesterol (CHO), triglyceride (TG), high density lipoprotein-cholesterol
      (HDL-C), low density lipoprotein-cholesterol (LDL-C) and glucose (Glu) were measured at 0, 7
      and 12 months of treatment by auto-analyzer.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Table 1 Study Specific Characteristic Part One</measure>
    <time_frame>at baseline</time_frame>
    <description>The percentage of female, race, hypertenion history, diabetes history, and hyperlipemia history was calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Table 1 Study Specific Characteristic of Age</measure>
    <time_frame>at baseline</time_frame>
    <description>the mean and standard deviation of age was calculated in four groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Table 1 Study Specific Characteristic of Body Mass Index (BMI)</measure>
    <time_frame>at baseline</time_frame>
    <description>the mean and standard deviation of BMI in four groups was calculated</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Table 1 Study Specific Characteristic of Blood Pressure (BP)</measure>
    <time_frame>at baseline</time_frame>
    <description>systolic BP and diastolic BP in four groups was measure twice between 15minutes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Table 1 Study Specific Characteristic of Serum Carotenoids</measure>
    <time_frame>at baseline</time_frame>
    <description>serum major carotenoids, including lutein, zeaxanthin, beta-carotene, and lycopene concentration were measured by hyper-pressure liquid chromatography (HPLC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of Right Common Carotid Arterial Stiffness Parameter β(R-β) at Baseline and After 12 Months</measure>
    <time_frame>at baseline and after 12 months</time_frame>
    <description>Arterial stiffness was measured by using a high-resolution B-mode carotid ultrasound with echo-tracking system (Aloka prosound α-10, Aloka Co. Ltd., Tokyo, Japan).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dietary Intake of Energy During the Study Periods</measure>
    <time_frame>at baseline and 12 months</time_frame>
    <description>Dietary intake was assessed at baseline and after 12months by using 3 consecutive 24-hour recalls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dietary Intake of Vitamin C,Vitamin E, Lutein Plus Zeaxanthin and Lycopene During the Study Periods</measure>
    <time_frame>at baseline and 12 months</time_frame>
    <description>Dietary intake of Vitamin C,Vitamin E, Lutein plus zeaxanthin and Lycopene was assessed at baseline and after 12months by using 3 consecutive 24-hour recalls.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">192</enrollment>
  <condition>Carotid Atherosclerosis</condition>
  <condition>Carotid Intimal Medial Thickness 1</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>early atherosclerosis cases, received starch in hard shell gelatine capsules, once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lutein group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>early atherosclerosis cases, received 20mg lutein, once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>early atherosclerosis cases, received 20mg lutein plus 20mg lycopene, once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal lutein control group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20mg lutein for subjects free from atherosclerosis, once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>one gelatine capsule containing starch per day, for 12 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lutein group</intervention_name>
    <description>one gelatine capsule containing 20mg lutein per day, for 12 months</description>
    <arm_group_label>Lutein group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Combination group</intervention_name>
    <description>one gelatine capsule containing 20mg lutein and 20 mg lycopene per day, for 12 months</description>
    <arm_group_label>Combination group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Normal lutein control group</intervention_name>
    <description>subjects without early atherosclerosis, treated with one gelatine capsule containing 20mg lutein per day, for 12 months</description>
    <arm_group_label>Normal lutein control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  early atherosclerosis;

          -  aged 45 to 68 years;

          -  Han nationality

        Exclusion Criteria:

          -  history of myocardial infarction,

          -  stroke,

          -  revascularization,

          -  coronary by-pass operation,

          -  local carotid IMT &gt; 1300μm or supplemental vitamin and/or mineral use for ≥ 4 week
             before the start of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>68 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaoming Lin, M.M.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Haidian District</name>
      <address>
        <city>Beijing</city>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Zou Z, Xu X, Huang Y, Xiao X, Ma L, Sun T, Dong P, Wang X, Lin X. High serum level of lutein may be protective against early atherosclerosis: the Beijing atherosclerosis study. Atherosclerosis. 2011 Dec;219(2):789-93. doi: 10.1016/j.atherosclerosis.2011.08.006. Epub 2011 Aug 10.</citation>
    <PMID>21872250</PMID>
  </reference>
  <verification_date>June 2013</verification_date>
  <!-- Old date names will be dropped in a few months (sometime in 2018)                        -->
  <lastchanged_date>June 18, 2013</lastchanged_date>
  <firstreceived_date>February 13, 2012</firstreceived_date>
  <firstreceived_results_date>July 26, 2012</firstreceived_results_date>
  <!-- New date names                                                                           -->
  <study_first_submitted>February 13, 2012</study_first_submitted>
  <study_first_submitted_qc>February 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2012</study_first_posted>
  <results_first_submitted>July 26, 2012</results_first_submitted>
  <results_first_submitted_qc>September 13, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 15, 2012</results_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2013</last_update_posted>
  <!-- End of dates                                                                             -->
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Xiaoming Lin</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>early atherosclerosis</keyword>
  <keyword>serum lutein</keyword>
  <keyword>serum lycopene</keyword>
  <keyword>intima-media thickness</keyword>
  <keyword>arterial stiffness</keyword>
  <keyword>combined effect</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Carotid Artery Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lycopene</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>starch in hard shell gelatine capsules</description>
        </group>
        <group group_id="P2">
          <title>Lutein Group</title>
          <description>20mg lutein per day</description>
        </group>
        <group group_id="P3">
          <title>Lutein and Lycopene Group</title>
          <description>lutein plus lycopene group</description>
        </group>
        <group group_id="P4">
          <title>Normal Lutein Group</title>
          <description>subjects without early atherosclerosis</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="48"/>
                <participants group_id="P4" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="40"/>
                <participants group_id="P4" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>starch in hard shell gelatine capsules</description>
        </group>
        <group group_id="B2">
          <title>Lutein Group</title>
          <description>20mg lutein per day</description>
        </group>
        <group group_id="B3">
          <title>Lutein and Lycopene Group</title>
          <description>lutein plus lycopene group</description>
        </group>
        <group group_id="B4">
          <title>Normal Lutein Group</title>
          <description>subjects without early atherosclerosis</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="48"/>
            <count group_id="B2" value="48"/>
            <count group_id="B3" value="48"/>
            <count group_id="B4" value="48"/>
            <count group_id="B5" value="192"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="46"/>
                    <measurement group_id="B5" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.4" spread="5.0"/>
                    <measurement group_id="B2" value="57.4" spread="4.4"/>
                    <measurement group_id="B3" value="57.3" spread="4.9"/>
                    <measurement group_id="B4" value="53.8" spread="5.8"/>
                    <measurement group_id="B5" value="56.5" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="48"/>
                    <measurement group_id="B5" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Table 1 Study Specific Characteristic Part One</title>
        <description>The percentage of female, race, hypertenion history, diabetes history, and hyperlipemia history was calculated.</description>
        <time_frame>at baseline</time_frame>
        <population>We conducted a per protocol analysis of all the subjects who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (P Group)</title>
            <description>starch in hard shell gelatine capsules</description>
          </group>
          <group group_id="O2">
            <title>Lutein Group (L Group)</title>
            <description>early atherosclerosis case received 20mg lutein</description>
          </group>
          <group group_id="O3">
            <title>Lutein and Lycopene Group (LL Group)</title>
            <description>received 20mg lutein and 20mg lycopene</description>
          </group>
          <group group_id="O4">
            <title>Normal Lutein Control Group (NL Group)</title>
            <description>subjects free from atherosclerosis received 20mg lutein</description>
          </group>
        </group_list>
        <measure>
          <title>Table 1 Study Specific Characteristic Part One</title>
          <description>The percentage of female, race, hypertenion history, diabetes history, and hyperlipemia history was calculated.</description>
          <population>We conducted a per protocol analysis of all the subjects who completed the study.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.8"/>
                    <measurement group_id="O2" value="59.8"/>
                    <measurement group_id="O3" value="59.1"/>
                    <measurement group_id="O4" value="72.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Race (Han people)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertension history</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.4"/>
                    <measurement group_id="O2" value="57.4"/>
                    <measurement group_id="O3" value="56.8"/>
                    <measurement group_id="O4" value="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetes history</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2"/>
                    <measurement group_id="O2" value="14.9"/>
                    <measurement group_id="O3" value="13.6"/>
                    <measurement group_id="O4" value="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperlipemia history</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.2"/>
                    <measurement group_id="O2" value="72.3"/>
                    <measurement group_id="O3" value="75.0"/>
                    <measurement group_id="O4" value="65.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was &quot;no group difference&quot;</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05 (two sides)</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Table 1 Study Specific Characteristic of Age</title>
        <description>the mean and standard deviation of age was calculated in four groups</description>
        <time_frame>at baseline</time_frame>
        <population>We conducted a per protocol analysis of all the subjects who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (P Group)</title>
            <description>starch in hard shell gelatine capsules</description>
          </group>
          <group group_id="O2">
            <title>Lutein Group (L Group)</title>
            <description>early atherosclerosis case received 20mg lutein</description>
          </group>
          <group group_id="O3">
            <title>Combination Group (LL Group)</title>
            <description>received 20mg lutein and 20mg lycopene</description>
          </group>
          <group group_id="O4">
            <title>Normal Lutein Control Group (NL Group)</title>
            <description>subjects free from atherosclerosis received 20mg lutein</description>
          </group>
        </group_list>
        <measure>
          <title>Table 1 Study Specific Characteristic of Age</title>
          <description>the mean and standard deviation of age was calculated in four groups</description>
          <population>We conducted a per protocol analysis of all the subjects who completed the study.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.4" spread="5.0"/>
                    <measurement group_id="O2" value="57.4" spread="4.4"/>
                    <measurement group_id="O3" value="57.3" spread="4.9"/>
                    <measurement group_id="O4" value="53.8" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was &quot;no group difference&quot;</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.992</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05 (two sides)</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Table 1 Study Specific Characteristic of Body Mass Index (BMI)</title>
        <description>the mean and standard deviation of BMI in four groups was calculated</description>
        <time_frame>at baseline</time_frame>
        <population>We conducted a per protocol analysis of all the subjects who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (P Group)</title>
            <description>starch in hard shell gelatine capsules</description>
          </group>
          <group group_id="O2">
            <title>Lutein Group (L Group)</title>
            <description>early atherosclerosis case received 20mg lutein</description>
          </group>
          <group group_id="O3">
            <title>Combination Group (LL Group)</title>
            <description>received 20mg lutein and 20mg lycopene</description>
          </group>
          <group group_id="O4">
            <title>Normal Lutein Control Group (NL Group)</title>
            <description>subjects free from atherosclerosis received 20mg lutein</description>
          </group>
        </group_list>
        <measure>
          <title>Table 1 Study Specific Characteristic of Body Mass Index (BMI)</title>
          <description>the mean and standard deviation of BMI in four groups was calculated</description>
          <population>We conducted a per protocol analysis of all the subjects who completed the study.</population>
          <units>Kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.3" spread="2.6"/>
                    <measurement group_id="O2" value="25.4" spread="3.2"/>
                    <measurement group_id="O3" value="24.8" spread="3.2"/>
                    <measurement group_id="O4" value="24.1" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was &quot;no group difference&quot;</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.672</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05 (two sides)</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Table 1 Study Specific Characteristic of Blood Pressure (BP)</title>
        <description>systolic BP and diastolic BP in four groups was measure twice between 15minutes</description>
        <time_frame>at baseline</time_frame>
        <population>We conducted a per protocol analysis of all the subjects who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (P Group)</title>
            <description>starch in hard shell gelatine capsules</description>
          </group>
          <group group_id="O2">
            <title>Lutein Group (L Group)</title>
            <description>early atherosclerosis case received 20mg lutein</description>
          </group>
          <group group_id="O3">
            <title>Lutein and Lycopene Group (LL Group)</title>
            <description>received 20mg lutein and 20mg lycopene</description>
          </group>
          <group group_id="O4">
            <title>Normal Lutein Control Group (NL Group)</title>
            <description>subjects free from atherosclerosis received 20mg lutein</description>
          </group>
        </group_list>
        <measure>
          <title>Table 1 Study Specific Characteristic of Blood Pressure (BP)</title>
          <description>systolic BP and diastolic BP in four groups was measure twice between 15minutes</description>
          <population>We conducted a per protocol analysis of all the subjects who completed the study.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic BP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129.7" spread="14.3"/>
                    <measurement group_id="O2" value="125.5" spread="16.4"/>
                    <measurement group_id="O3" value="126.0" spread="15.5"/>
                    <measurement group_id="O4" value="117.7" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic BP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.6" spread="10.6"/>
                    <measurement group_id="O2" value="80.5" spread="9.6"/>
                    <measurement group_id="O3" value="80.5" spread="9.6"/>
                    <measurement group_id="O4" value="77.2" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was &quot;no group difference&quot;</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.402</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05 (two sides)</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Table 1 Study Specific Characteristic of Serum Carotenoids</title>
        <description>serum major carotenoids, including lutein, zeaxanthin, beta-carotene, and lycopene concentration were measured by hyper-pressure liquid chromatography (HPLC)</description>
        <time_frame>at baseline</time_frame>
        <population>We conducted a per protocol analysis of all the subjects who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (P Group)</title>
            <description>starch in hard shell gelatine capsules</description>
          </group>
          <group group_id="O2">
            <title>Lutein Group (L Group)</title>
            <description>early atherosclerosis case received 20mg lutein</description>
          </group>
          <group group_id="O3">
            <title>Combination Group (LL Group)</title>
            <description>early atherosclerosis cases received 20mg lutein and 20mg lycopene</description>
          </group>
          <group group_id="O4">
            <title>Normal Lutein Control Group (NL Group)</title>
            <description>subjects free from atherosclerosis received 20mg lutein</description>
          </group>
        </group_list>
        <measure>
          <title>Table 1 Study Specific Characteristic of Serum Carotenoids</title>
          <description>serum major carotenoids, including lutein, zeaxanthin, beta-carotene, and lycopene concentration were measured by hyper-pressure liquid chromatography (HPLC)</description>
          <population>We conducted a per protocol analysis of all the subjects who completed the study.</population>
          <units>μg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lutein</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.07"/>
                    <measurement group_id="O2" value="0.19" spread="0.14"/>
                    <measurement group_id="O3" value="0.20" spread="0.11"/>
                    <measurement group_id="O4" value="0.18" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Zeaxanthin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.034" spread="0.022"/>
                    <measurement group_id="O2" value="0.034" spread="0.018"/>
                    <measurement group_id="O3" value="0.035" spread="0.022"/>
                    <measurement group_id="O4" value="0.030" spread="0.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>beta-carotene</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.087" spread="0.026"/>
                    <measurement group_id="O2" value="0.069" spread="0.026"/>
                    <measurement group_id="O3" value="0.071" spread="0.031"/>
                    <measurement group_id="O4" value="0.058" spread="0.005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lycopene</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.106" spread="0.037"/>
                    <measurement group_id="O2" value="0.092" spread="0.043"/>
                    <measurement group_id="O3" value="0.104" spread="0.074"/>
                    <measurement group_id="O4" value="0.098" spread="0.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was &quot;no group difference&quot;</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.636</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05 (two sides)</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes of Right Common Carotid Arterial Stiffness Parameter β(R-β) at Baseline and After 12 Months</title>
        <description>Arterial stiffness was measured by using a high-resolution B-mode carotid ultrasound with echo-tracking system (Aloka prosound α-10, Aloka Co. Ltd., Tokyo, Japan).</description>
        <time_frame>at baseline and after 12 months</time_frame>
        <posting_date>12/3333</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dietary Intake of Energy During the Study Periods</title>
        <description>Dietary intake was assessed at baseline and after 12months by using 3 consecutive 24-hour recalls.</description>
        <time_frame>at baseline and 12 months</time_frame>
        <posting_date>12/3333</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dietary Intake of Vitamin C,Vitamin E, Lutein Plus Zeaxanthin and Lycopene During the Study Periods</title>
        <description>Dietary intake of Vitamin C,Vitamin E, Lutein plus zeaxanthin and Lycopene was assessed at baseline and after 12months by using 3 consecutive 24-hour recalls.</description>
        <time_frame>at baseline and 12 months</time_frame>
        <posting_date>12/3333</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>adverse event data were collected in 12months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>early atherosclerosis cases, received starch in hard shell gelatine capsules, once a day</description>
        </group>
        <group group_id="E2">
          <title>Lutein Group</title>
          <description>early atherosclerosis cases, received 20mg lutein, once a day</description>
        </group>
        <group group_id="E3">
          <title>Combination Group</title>
          <description>early atherosclerosis cases, received 20mg lutein plus 20mg lycopene, once a day</description>
        </group>
        <group group_id="E4">
          <title>Normal Lutein Control Group</title>
          <description>20mg lutein for subjects free from atherosclerosis, once a day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Zhiyong Zou</name_or_title>
      <organization>Peking University</organization>
      <phone>+8610-13581525193</phone>
      <email>harveyzou2002@bjmu.edu.cn</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
